XtalPi ^Company

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enables pharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide.

Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.

Stock Symbol: 2228
Founders: Jian Ma,Lipeng Lai,Shuhao Wen

Technologies: XtalPi (2228.HK), a publicly listed pharmaceutical technology company founded by MIT quantum physicists, integrates quantum mechanics, artificial intelligence, and automation to accelerate drug and materials discovery. Key technologies include: Intelligent Digital Drug Discovery and Development (ID4) Platform, Quantum Physics-Based First-Principle Calculations, AI-Driven Molecular Design & Large Language Models, ID4Inno™ Small-Molecule Drug Discovery Platform, Autonomous Robotic Laboratories, Design-Make-Test-Analyze (DMTA) Cycles, Cloud Supercomputing Infrastructure, AI for Biologics & Molecular Glue Discovery, Material Science Applications, Next-Generation Molecular Modeling Platform (collaboration with Pfizer).